

Title of Trial: Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™)

Investigational Product: efalizumab

Trial No.: 27577

Study Centers: Not available

Trial Initiation Date: 11 Jun 2008

Trial Completion Date: 31 Jul 2009

Development Phase: Phase 4

Publication (reference): None

Study Objectives: Data not available

Methodology: Data not available

Number of Subjects (Planned and Analyzed): Data not available

Diagnosis and Main Criteria for Inclusion/Exclusion: Data not available

Study Treatment: Data not available

Criteria for Evaluation: Data not available

Statistical Methods: Data not available

Results: Data not available

Conclusions: Data not available

Due diligence was done and all potential information sources have been exhausted. No source documents for this study were identified. Due to non-availability of clinical study reports and synopses, results were not posted in EudraCT database

Merck KGaA

These results are supplied for informational purposes only.